Normal human speech emits droplets capable of carrying the novel coronavirus (SARS-CoV-2) that causes COVID-19, researchers say. The droplets lingered in the air for up to 14 minutes in a recent study, which could help explain why the disease has spread so rapidly.
On the other hand, a separate study turned up no infectious particles of SARS-CoV-2 in stool samples.
The findings could provide clues about how best to limit the disease’s spread. “Fecal–oral is not a happening thing,” said Andrew Noymer, PhD, MSc, associate professor of population health and disease prevention at the University of California, Irvine. “I think this reinforces the importance of masking.”
SARS-CoV-2 floats in particles in the air, and public health officials believe this is the primary route of transmission between people. Less clear is whether someone has to cough or sneeze to expel enough droplets to infect another person with COVID-19, or whether talking and other activities also spread the disease.
A new nationwide US observational study suggests that ACE inhibitors may protect against severe illness in older people with COVID-19, prompting the start of a randomized clinical trial to test the strategy.
In addition, a new meta-analysis of all the available data on the use of ACE inhibitors and angiotensin-receptor blockers (ARBs) in COVID-19–infected patients has concluded that these drugs are not associated with more severe disease and do not increase susceptibility to infection.
The observational study, which was published on the MedRxiv preprint server on May 19 and has not yet been peer reviewed, was conducted by the health insurance company United Heath Group and by the Yale University School of Medicine, in New Haven, Connecticut.
The investigators analyzed data from 10,000 patients from across the United States who had tested positive for COVID-19, who were enrolled in Medicare Advantage insurance plans or were commercially insured, and who had received a prescription for one or more antihypertensive medications.
Patients with immune thrombocytopenia (ITP) are undergoing fewer and fewer splenectomies later and later in the disease course, which is resulting in lower gains from the procedure, say UK researchers, who question its ongoing role.
The research was published as an abstract from the British Society for Haematology 60th Annual Scientific Meeting, which was cancelled due to the COVID-19 pandemic.
Role of Splenectomy ‘Unclear’
Dr Sophie Todd, Royal London Hospital, Barts Health NHS Trust, London, and colleagues studied more than 3800 ITP patients diagnosed in the UK from the early 1950s.
The results, which are an update of findings presented at the 24th European Heart Association Congress in June 2019, show that around a third of patients underwent splenectomy in the 1990s, falling to less than 4% since 2009.
This has corresponded to an increase in the use of medical therapies, with the procedure consequently performed later on in the treatment course.
You must be logged in to post a comment.